Vertex Pharmaceuticals VRTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's cash & equivalents?
- Vertex Pharmaceuticals (VRTX) reported cash & equivalents of $5.5B in Q1 2026.
- How has Vertex Pharmaceuticals's cash & equivalents changed year-over-year?
- Vertex Pharmaceuticals's cash & equivalents increased by 17.5% year-over-year, from $4.69B to $5.5B.
- What is the long-term trend for Vertex Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's cash & equivalents has grown at a 12.7% compound annual growth rate (CAGR), from $2.8B to $5.09B.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.